HomeCompareTSBX vs QYLD

TSBX vs QYLD: Dividend Comparison 2026

TSBX yields 563.38% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TSBX wins by $156404.02M in total portfolio value
10 years
TSBX
TSBX
● Live price
563.38%
Share price
$0.36
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$156404.05M
Annual income
$115,926,179,183.70
Full TSBX calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — TSBX vs QYLD

📍 TSBX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTSBXQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TSBX + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TSBX pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TSBX
Annual income on $10K today (after 15% tax)
$47,887.32/yr
After 10yr DRIP, annual income (after tax)
$98,537,252,306.14/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, TSBX beats the other by $98,537,247,495.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TSBX + QYLD for your $10,000?

TSBX: 50%QYLD: 50%
100% QYLD50/50100% TSBX
Portfolio after 10yr
$78202.04M
Annual income
$57,963,092,421.51/yr
Blended yield
74.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on TSBX right now

TSBX
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
Price Target
$0.50
+40.8% upside vs current
Range: $0.50 — $0.50
Altman Z
-23.2
Piotroski
2/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TSBX buys
0
QYLD buys
0
No recent congressional trades found for TSBX or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTSBXQYLD
Forward yield563.38%11.92%
Annual dividend / share$2.00$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$156404.05M$25.4K
Annual income after 10y$115,926,179,183.70$5,659.31
Total dividends collected$152979.84M$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: TSBX vs QYLD ($10,000, DRIP)

YearTSBX PortfolioTSBX Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$67,038$56,338.03$10,352$1,192.36+$56.7KTSBX
2$424,702$352,971.06$10,830$1,347.57+$413.9KTSBX
3$2,544,295$2,089,864.53$11,460$1,539.07+$2.53MTSBX
4$14,423,258$11,700,861.61$12,275$1,777.84+$14.41MTSBX
5$77,424,065$61,991,178.81$13,323$2,078.95+$77.41MTSBX
6$393,842,555$310,998,805.50$14,667$2,463.34+$393.83MTSBX
7$1,899,912,512$1,478,500,978.24$16,396$2,960.57+$1899.90MTSBX
8$8,698,653,014$6,665,746,626.53$18,631$3,612.97+$8698.63MTSBX
9$37,829,785,494$28,522,226,769.44$21,548$4,482.15+$37829.76MTSBX
10$156,404,049,663$115,926,179,183.70$25,398$5,659.31+$156404.02MTSBX

TSBX vs QYLD: Complete Analysis 2026

TSBXStock

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

Full TSBX Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this TSBX vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TSBX vs SCHDTSBX vs JEPITSBX vs OTSBX vs KOTSBX vs MAINTSBX vs XYLDTSBX vs JEPQTSBX vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.